Schedules to the Security Purchase Agreement



 EXHIBIT 10.9 
 Schedule A 
 LOCATION OF DEBTORS ACCOUNTS AND RECORDS 
 Accentia Biopharmaceuticals, Inc. 
 324 South Hyde Park Avenue, Suite 350

 Tampa, Florida 33606 
 Accentia Specialty Pharmacy, Inc.

 324 South Hyde Park Avenue, Suite 350 
 Tampa, Florida 33606

 AccentRx, Inc. 
 324 South Hyde Park Avenue, Suite 350

 Tampa, Florida 33606 







 Schedule B 
 PERMITTED LIENS 
 None. 







 Schedule C 
 FILINGS OR RECORDATIONS IN GOVERNMENTAL OR REGULATORY AUTHORITY, 
 AGENCY, OR RECORDING OFFICE 
 At closing, all security interests in the Collateral, except those granted hereby to the Secured Parties under this Agreement, will be released.








 Schedule D 
 DEBTORS’ STATE OF ORGANIZATION 
  

					
	 Company Name
	 	 Date of Incorporation
	 	 State of Incorporation

			
	Accentia Biopharmaceuticals, Inc.	 	March 26, 2002	 	Florida
		 		 	P02000033509
			
	Accentia Specialty Pharmacy, Inc.	 	April 27, 2004	 	Florida
		 		 	P04000068477
			
	AccentRX, Inc.	 	March 26, 2002	 	Florida
		 		 	P02000033522








 Schedule E 
 DEBTORS’ NAMES 
  

	(i)	Debtor Name: Accentia Biopharmaceuticals, Inc. 

  

	(ii)	Does not have any trade names 

  

	(iii)	Accentia, Inc. changed on May 11, 2005 

  

	(iv)	Accentia Specialty Pharmacy – merged on April 27, 2004 

  

	 	TEAMM Pharmaceuticals, Inc. – merged on April 30, 2003 

  

	 	Biovest International, Inc. – investment, majority shareholder on June 16, 2003 

  

	(i)	Debtor Name: Accentia Specialty Pharmacy, Inc. 

  

	(ii)	Does not have any trade names 

  

	(iii)	Has not used any name other than that stated for the preceding five years 

  

	(iv)	Was acquired and merged into Accentia Biopharmaceuticals, Inc. on April 27, 2004 

  


	(i)	Debtor Name: AccentRx, Inc. 

  

	(ii)	Does not have any trade names 

  

	(iii)	Has not used any name other than that stated for the preceding five years 

  

	(iv)	Was not acquired or merged into any Debtor within the past five years 








 Schedule F 
 Intellectual Property Related to SinuNase and Revimmune; including License Rights (In-Licensed) 
  

																									
	 Atty
 Docket #
	 	 Country
	 	 Status
	 	 Application #
	 	 Pub. #
	 	 Filing
 Date
	 	 Priority
	 	 Title
	 	 Owner/Assignee
	 	 Inventors
	 	 Patent
#
	 	 Issue
Date
	 	 Assoc.
Tech.

													
	ACZ-014	 	US	 	PENDING	 	11/777,890	 		 	7/13/2007	 	 2/9/07 - 60/900,593
 7/13/2006 - 60/830,528
	 	METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.	 		 		 	SinuNase
													
	ACZ-014PC	 	PCT	 	PENDING	 	PCT/US2007/016000	 	WO 2008/008494 (1/17/08)	 	7/13/2007	 	 2/9/07 - 60/900,593
 7/13/2006 - 60/830,528
	 	METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.	 		 		 	SinuNase
													
	ACZ-016PC	 	PCT	 	PENDING	 	PCT/US2007/080333	 	WO 2008/063756 (5/29/2008)	 	10/3/2007	 	 1/19/07 - 60/881,270
 10/3/06 -
60/849,028
	 	MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS	 	Accentia, Biopharmaceuticals Inc.	 	Francis E. O’Donnell, Jr.; Donald Deroo	 		 		 	SinuNase
													
	ACZ-024-1	 	US	 	PENDING	 	61/027,736	 		 	2/11/2008	 		 	MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B LIQUID FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Donald Deroo	 		 		 	SinuNase
													
	ACZ-026-1	 	US	 	PENDING	 	61/038,679	 		 	3/21/2008	 		 	DEVICES AND METHODS FOR DETERMINING THE EFFICACY OF A NON-SURGICAL INTERVENTION FOR THE TREATMENT OR PREVENTION OF CHRONIC RHINOSINUSITIS	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Angelos M. Stergiou; Susan Bonitz; Carlos Santos	 		 		 	SinuNase
													
	ACZ-027-1	 	US	 	PENDING	 	61/041,866	 		 	4/2/2008	 		 	FORMULATIONS, DEVICES AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Angelos M. Stergiou	 		 		 	SinuNase











																									
	 Atty
 Docket #
	 	 Country
	 	 Status
	 	 Application #
	 	 Pub. #
	 	 Filing
 Date
	 	 Priority
	 	 Title
	 	 Owner/Assignee
	 	 Inventors
	 	 Patent
#
	 	 Issue
Date
	 	 Assoc.
Tech.

													
	JHV-060.25	 	PCT	 	PENDING	 	PCT/US2007/78521	 	WO 2008/034074 (3/20/08)	 	9/14/2007	 	9/15/06 - 60/844,830	 	USE OF HIGH DOSE CYCLOPHOSPHAMIDE IN COMBINATION WITH ANTI-IDIOTYPIC VACCINES IN ANTI-CANCER THERAPY	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	JHV-059.25	 	PCT	 	PENDING	 	PCT/US2007/78518	 	WO 2008/034071 (3/20/08)	 	9/14/2007	 	9/15/06 - 60/844,829	 	METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE CYCLOPHOSPHAMIDE TREATMENT	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	JHV-062.25	 	PCT	 	PENDING	 	PCT/US2007/81614	 	Anticipated Pub. Date: 5/8/08	 	10/17/2007	 	11/3/06 - 60/856,698	 	USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	RIZ-006-1	 	US	 	PENDING	 	60/989,628	 		 	11/21/2007	 		 	METHODS OF PROVIDING A SYSTEM OF CARE FOR A HIGH-DOSE REGIMEN OF AN OXAZAPHOSPHORINE DRUG	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	ACZ-025-1	 	US	 	PENDING	 	61/038,033	 		 	3/19/2008	 		 	METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE OXAZAPHOSPHORINE TREATMENT	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune

  










																									
	 Atty
 Docket #
	 	 Country
	 	 Status
	 	 Application #
	 	 Pub. #
	 	 Filing
Date
	 	 Priority
	 	 Title
	 	 Owner/Assignee
	 	 Inventors
	 	 Patent
#
	 	 Issue
Date
	 	 Assoc.
Tech.

													
	RIZ-007-1	 	US	 	PENDING	 	61/022,774	 		 	1/22/2008	 		 	USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATMENT AND PREVENTION OF TRANSPLANT REJECTION	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert Brodsky; Richard J. Jones; Susan Bonitz; Francis E. O’Donnell, Jr.; Carlos Santos	 		 		 	Revimmune

 SinuNase Agreements 
 1 - License Agreement between Mayo Foundation and Accentia Biopharmaceuticals, Inc., effective February 10, 2004, amended Dec. 23, 2004, Aug. 22, 2006, April 16, 2007, August 30, 2007, and
pending 
 2 - Marketing Agreement between TEAMM Pharmaceuticals, Inc. and IMMCO Diagnostics, Inc., effective June 30, 2005 
 3 - Option Agreement between Mayo Foundation and Accentia Biopharmaceuticals, Inc., effective December 6, 2005, amended July 20, 2006, May 9, 2007,
and pending 
 4 - Non-exclusive Sublicense between Accentia Specialty Pharmacy, Inc. and JCB Laboratories, LLC, effective January 1, 2007 

5 - Non-exclusive Sublicense between Accentia Specialty Pharmacy, Inc. and AnazaoHealth Corporation, effective February 1, 2007 
 Revimmune Agreements 
 1 - Sublicense Agreement between
Revimmune, LLC and Accentia Biopharmaceuticals, Inc., effective February 27, 2007, amended April 18, 2008 and June 16, 2008 
 2 - License
Agreement between Johns Hopkins University and Revimmune, LLC, effective February 20, 2006 
 3 - License Agreement between Accentia Biopharmaceuticals,
Inc. and Biovest International, Inc., pending 









 Schedule F 
 Intellectual Property Related to SinuNase and Revimmune; including License Rights (In-Licensed) 
 (Continued) 
 SinuNase 
 Trademarks

  

																	
	 Atty Docket #
	  	 Country
	  	 Trademark
	  	 Status
	  	 Owner
	  	 Application #
	  	 Filing Date
	  	 Reg. #
	  	 Reg. Date

									
	ACZ-0705	  	US	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	78/540118	  	12/30/2004	  		  	
									
	ACZ-0705AU	  	Australia	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	1092277	  	12/21/2005	  		  	
									
	ACZ-0705CA	  	Canada	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	1242790	  	1/6/2005	  		  	
									
	ACZ-0705CTM	  	Europe	  	SINUNASE	  	Registered	  	Accentia Biopharmaceuticals, Inc.	  	4236147	  	1/10/2005	  	4236147	  	
									
	ACZ-0705JP	  	Japan	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	2005-120651	  	12/22/2005	  	4977873	  	
									
	ACZ-0708	  	US	  	SINUTEST	  	Published	  	Accentia Biopharmaceuticals, Inc.	  	78/664701	  	7/6/2005	  		  	
									
	ACZ-0708AU	  	Australia	  	SINUTEST	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	1092278	  	12/21/2005	  	1092278	  	
									
	ACZ-0708CA	  	Canada	  	SINUTEST	  	Pending	  	Accentia Biopharmaceuticals, Inc.	  	1284178	  	12/21/2005	  		  	
									
	ACZ-0708CTM	  	Europe	  	SINUTEST	  	Published	  	Accentia Biopharmaceuticals, Inc.	  	4805248	  	12/23/2005	  		  	








 SinuNase 
 Trademarks 
  

																	
	 Atty Docket #
	  	 Country
	  	 Trademark
	  	 Status
	  	 Owner
	  	 Application #
	  	 Filing Date
	  	 Reg. #
	  	 Reg. Date

									
	ACZ-0708JP	  	Japan	  	SINUTEST	  	FILED	  	 Accentia Biopharmaceuticals,
 Inc.
	  	2005-120653	  	12/22/2005	  	5034132	  	
									
	ACZ-0709	  	US	  	SINULES	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	78/678158	  	7/26/2005	  		  	
									
	ACZ-0710	  	US	  	FUNGINASE	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	78/830090	  	3/6/2006	  		  	
									
	ACZ-0712	  	US	  	SINUSEPTIC	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	78/936216	  	7/24/2006	  		  	
									
	ACZ-0714	  	US	  	MUCONASE	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	77/36732	  	12/20/2007	  		  	








 Schedule pp 
 FEDERAL ASSIGNMENT OF CLAIMS ACT 
  

			
	Accentia Biopharmaceuticals, Inc.	  	NONE
		
	Accentia Specialty Pharmacy, Inc.	  	NONE
		
	AccentRx, Inc.	  	NONE